A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy
in patients with metastatic or locally advanced malignancies. The study will be conducted in
2 cohorts: Dose Escalation and Dose Expansion.